Multi‐omics analyses reveal distinct molecular characteristics and transformation mechanisms of stage I– III micropapillary lung adenocarcinoma
The Journal of Pathology · 2025
DOI: 10.1002/path.6416 ↗At a glance
Journal article in The Journal of Pathology, 2025. Written by Yang Qu and 11 co-authors. Institution: Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and…. Major MEDLINE topics: Lung Neoplasms, Adenocarcinoma of Lung, Biomarkers, Tumor, Cell Transformation, Neoplastic. Cited 2 times so far (Crossref); 43 references. Funded by: Beijing Hope Run Special Fund of Cancer Foundation of China.
Abstract (original language)
The micropapillary (MIP) pattern is a high‐grade histological subtype of lung adenocarcinoma (LUAD) with poor prognosis. In this study, surgically resected tumor samples from 101 patients with stage I–III MIP–LUAD (MIP ≥30%) were microdissected to separate MIP components from non‐MIP components, all of which underwent RNA and DNA whole‐exome sequencing (WES). The genomic and transcriptomic landscapes of MIP and non‐MIP components within MIP‐enriched tumor tissues demonstrated remarkable similarities, notably marked by high epidermal growth factor receptor (EGFR) alteration frequencies. However, when compared to MIP‐naïve LUAD tissues, MIP components showed higher chromosomal instability and revealed 18 enriched alterations, encompassing EGFR mutations, EGFR amplifications, and CDKN2A/CDKN2B deletions, which all linked to upregulation of cell proliferation pathways and downregulation of immune pathways. Shared mutations were observed in 97.8% (91/93) of patients with paired DNA WES data for MIP and non‐MIP components within the same tissues, suggesting a common origin. The recurrence‐free survival analysis identified MACF1, PCLO, ADGRV1, and Fanconi Anemia pathway mutations as negative indicators. In all, we conducted an in‐depth analysis of the molecular characteristics and transformation mechanisms of MIP–LUAD, employing microdissection techniques to investigate the genomic and transcriptomic levels within a substantial cohort, providing insights for precision medicine of this aggressive cancer subtype. © 2025 The Pathological Society of Great Britain and Ireland.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China.
- Nanjing Geneseeq Technology Inc, Nanjing, PR China.
- Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, PR China.
- Department of Dermatology, Columbia University Irving Medical Center, Vagelos College of Physicians and Surgeons, New York, NY, USA.
ORCID profiles: Hanlin Chen, Shugeng Gao, Kang Shao
Funding
- Beijing Hope Run Special Fund of Cancer Foundation of China
Cite
APA
Qu, Y., Feng, X., Chen, H., Tan, F., Shao, A., Pang, J., Xue, Q., Zheng, B., Zheng, W., Ou, Q., Gao, S., & Shao, K. (2025). Multi‐omics analyses reveal distinct molecular characteristics and transformation mechanisms of stage I– III micropapillary lung adenocarcinoma. The Journal of Pathology. https://doi.org/10.1002/path.6416
Vancouver
Qu Y, Feng X, Chen H, Tan F, Shao A, Pang J, et al. Multi‐omics analyses reveal distinct molecular characteristics and transformation mechanisms of stage I– III micropapillary lung adenocarcinoma. The Journal of Pathology. 2025. doi:10.1002/path.6416
BibTeX
@article{Qu2025,
author = {Qu, Yang and Feng, Xiaoli and Chen, Hanlin and Tan, Fengwei and Shao, Anqi and Pang, Jiaohui and Xue, Qi and Zheng, Bo and Zheng, Wei and Ou, Qiuxiang and Gao, Shugeng and Shao, Kang},
title = {Multi‐omics analyses reveal distinct molecular characteristics and transformation mechanisms of stage I– III micropapillary lung adenocarcinoma},
journal = {The Journal of Pathology},
year = {2025},
doi = {10.1002/path.6416}
}
EUVIMED